Comparative Pharmacology
Head-to-head clinical analysis: SUPPRELIN versus VIADUR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SUPPRELIN versus VIADUR.
SUPPRELIN vs VIADUR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH) that acts as a potent inhibitor of gonadotropin secretion. Initially stimulates, then suppresses pituitary gonadotropin release (LH and FSH), leading to decreased testosterone and estrogen production.
Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist that stimulates pituitary gonadotropin release initially, followed by sustained suppression of pituitary gonadotropins due to receptor desensitization, leading to reduced testosterone production.
50 mcg subcutaneously once daily for the first month, then 25 mcg subcutaneously once daily for maintenance. Alternatively, 7.5 mg intramuscularly once monthly.
Leuprolide acetate implant 65 mg implanted subcutaneously in the inner aspect of the upper arm once yearly.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours following subcutaneous administration; this supports once-daily dosing.
The terminal elimination half-life of leuprolide acetate following subcutaneous administration is approximately 3 hours. In patients with renal impairment, half-life may be prolonged; however, no dose adjustment is recommended for mild-to-moderate impairment.
Primarily renal, with approximately 70-80% of histrelin excreted unchanged in urine; biliary/fecal excretion accounts for about 20-30%.
Leuprolide acetate is primarily eliminated via hepatic metabolism and renal excretion. Approximately 48% of the dose is recovered in urine over 24 hours, with 5% as unchanged drug. Fecal excretion accounts for about 5%.
Category C
Category C
GnRH Agonist
GnRH Agonist